Invesco S&P 500 Equal Weight Health Care ETF (RSPH) Valuation
RSPH valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 34.7 trailing earnings
- Forward P/E
- 16.1 analyst estimates
- Price / sales
- 1.25
- Price / book
- 3.54
- EV / EBITDA
- 14.2
- Earnings yield
- 2.88% inverse of P/E
- Dividend yield
- 0.94% of the holdings
- Return on equity
- 10.2% combined
- Net margin
- 3.6% combined
- Beta
- 0.79 weighted, vs S&P 500
RSPH valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| RSPH | 34.7 | 16.1 | 1.25 | 3.54 | 0.94% | 10.2% | 3.6% | 10.8% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
RSPH valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 99.97% | 34.7 | 16.1 | 1.25 | 3.54 | 0.94% | 10.2% |
RSPH earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How RSPH weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
RSPH largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 2.28% | — | 23.0 | 39.1 | — | −2.89% |
| ISRG | Intuitive Surgical, Inc. | 2.02% | 48.9 | 33.3 | 13.7 | — | 1.43% |
| ILMN | Illumina, Inc. | 2.00% | 49.0 | 40.3 | 8.8 | — | 1.42% |
| CRL | Charles River Laboratories International, Inc. | 1.95% | — | 22.4 | 3.6 | — | −1.08% |
| RVTY | Revvity, Inc. | 1.93% | 73.0 | 24.2 | 5.8 | 0.18% | 0.92% |
| MTD | Mettler-Toledo International Inc. | 1.93% | 36.6 | 28.5 | 7.9 | — | 1.83% |
| VEEV | Veeva Systems Inc. | 1.90% | 50.9 | 30.2 | 14.5 | — | 1.30% |
| ABBV | AbbVie Inc. | 1.81% | 80.6 | 16.4 | 7.8 | 2.42% | 0.78% |
| RMD | ResMed Inc. | 1.79% | 22.9 | 18.5 | 5.9 | 1.10% | 2.71% |
| A | Agilent Technologies, Inc. | 1.77% | 34.1 | 23.9 | 6.6 | 0.59% | 1.81% |
| ZTS | Zoetis Inc. | 1.77% | 13.1 | 12.0 | 3.4 | 2.67% | 4.72% |
| SYK | Stryker Corporation | 1.77% | 30.5 | 16.5 | 4.4 | 1.19% | 2.01% |
| ELV | Elevance Health Inc. | 1.76% | 19.0 | 13.7 | 0.5 | 1.61% | 3.22% |
| WST | West Pharmaceutical Services, Inc. | 1.76% | 49.4 | 37.0 | 8.1 | 0.23% | 1.23% |
| BIIB | Biogen Inc. | 1.75% | 41.3 | 13.9 | 3.4 | — | 1.47% |
| BDX | Becton, Dickinson and Company | 1.75% | 44.6 | 13.7 | 2.3 | 2.19% | 1.36% |
| PODD | Insulet Corporation | 1.74% | 26.4 | 54.9 | 3.2 | — | 2.28% |
| DHR | Danaher Corporation | 1.73% | 40.8 | 23.8 | 6.4 | 0.70% | 1.47% |
| CNC | Centene Corporation | 1.72% | — | 11.2 | 0.2 | — | −8.99% |
| IDXX | IDEXX Laboratories, Inc. | 1.71% | 39.8 | 31.4 | 9.7 | — | 1.49% |
| GEHC | GE HealthCare Technologies Inc. | 1.70% | 16.0 | 12.1 | 1.5 | 0.23% | 3.69% |
| WAT | Waters Corporation | 1.69% | 110.6 | 24.8 | 9.2 | — | 0.53% |
| CI | Cigna Corporation | 1.69% | 12.5 | 8.3 | 0.3 | 2.06% | 4.69% |
| VTRS | Viatris Inc. | 1.68% | — | 6.4 | 1.5 | 2.57% | −1.12% |
| STE | STERIS plc | 1.67% | 27.2 | 19.2 | 3.6 | 1.16% | 2.13% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About RSPH valuation
Adding up its 60 holdings with company data, RSPH trades at 34.7 times trailing earnings and 16.1 times analysts' forward estimates, with a price-to-book ratio of 3.54 and a dividend yield of 0.94%. Its earnings yield of 2.88% is 2.45 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 19.4% of the fund and earn 8.2% of its combined profit. Companies that lost money over the past year are 10.8% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 99.99% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: RSPH chart, RSPH performance, RSPH holdings, RSPH dividends.
RSPH valuation FAQ
What is the P/E ratio of RSPH?
Based on its holdings, RSPH has a trailing P/E of 34.7 and a forward P/E of 16.1 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of RSPH?
The trailing earnings yield is 2.88% (1 ÷ P/E) and the forward earnings yield 6.23%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is RSPH more expensive than the S&P 500?
RSPH trades at 34.7 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 16.1 and 19.9.
What is the price-to-book ratio of RSPH?
The holdings of RSPH trade at 3.54 times book value, with a combined return on equity of 10.2%.